Patent · US Expired

Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products

US6960351B2 · kind B2 · utility

22Cited by
40References
1Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 21, 2003
Grant dateNov 1, 2005
Priority date
Expiry dateSep 13, 2023

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/02
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual. The vehicle is particularly well-suited to delivery of insulin from immunoisolated islets of Langerhans, and can also be used advantageously for delivery of high molecular weight products, such as products larger than IgG. A method of making a biocompatible, immunoisolatory implantable vehicle, consisting in a first embodiment of a coextrusion process, and in a second embodiment of a stepwise process. A method for isolating cells within a biocompatible, immunoisolatory implantable vehicle, which protects the isolated cells from attack by the immune system of an individual in whom the vehicle is implanted. A method of providing a needed biological product or metabolic function to an individual, comprising implanting into …

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.